Table 2b.
Factors associated with SARS-CoV-2 IgG and Neutralising antibody positivity in Visit 2.
| Variable | IgG Antibody positivity (Visit 2) |
Neutralising Antibody positivity (Visit 2) |
||||||
|---|---|---|---|---|---|---|---|---|
| Risk | RR (95% CI) | Risk Difference (95% CI) | Risk | RR (95% CI) | Risk Difference (95% CI) | |||
| Gender | ||||||||
| Female | 5/37 (14%) | 1.1 (0.4 to 2.6) | 0.007 (-0.1 to 0.1) | 2/6 (33%) | 0.7 (0.2 to 2.2) | -0.2 (-0.6 to 0.3) | ||
| Male | 20/156 (13%) | Baseline | 11/22 (50%) | Baseline | ||||
| Shared Bedroom | ||||||||
| Yes | 7/87 (8%) | 0.5 (0.2 to 1.0) | -0.09 (-0.2 to -0.003) | 5/8 (63%) | 1.6 (0.7 to 3.3) | 0.23 (-0.2 to 0.6) | ||
| No | 18/102 (18%) | Baseline | 8/20 (40%) | Baseline | ||||
| Shared Bathroom | ||||||||
| Yes | 22/172 (13%) | 0.9 (0.3 to 2.7) | -0.01 (-0.2 to 0.1) | 11/24 (46%) | 0.9 (0.3 to 2.7) | -0.04 (-0.6 to 0.5) | ||
| No | 3/21 (14%) | Baseline | 2/4 (50%) | Baseline | ||||
| Bathroom shared with one other Army Colleague | ||||||||
| Yes | 16/72 (22%) | 2.9 (1.3 to 6.2) | 0.2 (0.04 to 0.3) | 8/17 (47%) | 1 (0.5 to 2.4) | 0.02 (-0.4 to 0.4) | ||
| No | 9/117 (8%) | Baseline | 5/11 (45%) | Baseline | ||||
| Smoke or Vape (limited data available) | ||||||||
| Yes | 3/8 (38%) | 0.5 (0.2-1.2) | -0.4(-0.8 to -0.1) | 0/3 | NA | -0.7 (-0.9 to -0.5) | ||
| No | 17/21 (81%) | Baseline | 12/17 (71%) | Baseline | ||||
| Asymptomatic cases by gender | ||||||||
| Asymptomatic Female | 5/29 (17%) | 2.1 (0.8 to 5.7) | 0.1 (-0.6 to 0.2) | 2/6 (33%) | 0.6 (0.2 to 2.1) | -0.2 (-0.7 to 0.3) | ||
| Asymptomatic Male | 9/109 (8%) | Baseline | 6/11 (55%) | Baseline | ||||
| Symptomatic cases by gender | ||||||||
| Symptomatic Female | 0/8 (0%) | NA | -0.2 (-0.4 to -0.1) | 0/0 | NA | NA | ||
| Symptomatic Male | 11/47 (23%) | Baseline | 5/11 (45%) | Baseline | ||||
| Close contact with a confirmed case | ||||||||
| Yes | 5/5 (100%) | 9.4 (6.2 to 14.2) | 0.9 (0.8 to 0.94) | 3/5 (60%) | 1.4 (0.6 to 3.2) | 0.17 (-0.3 to 0.6) | ||
| No | 20/188 (11%) | Baseline | 10/23 (43%) | Baseline | ||||
| Symptom Variable | IgG Antibody positivity |
Neutralising Antibody positivity |
||||||
|---|---|---|---|---|---|---|---|---|
| Risk | RR (95% CI) | Risk Difference (95% CI) | Risk | RR (95% CI) | Risk Difference (95% CI) | |||
| Any Symptoms | ||||||||
| Yes | 11/55 (20%) | 1.98 (0.96 to 4.1) | 0.1 (-0.02 to 0.2) | 5/11 (45%) | 0.97 (0.4 to 2.2) | -0.02 (-0.4 to 0.4) | ||
| No | 14/138 (10%) | Baseline | 8/17 (47%) | Baseline | ||||
| Fever | ||||||||
| Yes | 6/20 (30%) | 2.7 (1.2 to 6.0) | 0.2 (-0.02 to 0.4) | 4/6 (67%) | 1.6 (0.8 to 3.5) | 0.3 (-0.2 to 0.7) | ||
| No | 19/173 (11%) | Baseline | 9/22 (40%) | Baseline | ||||
| Cough | ||||||||
| Yes | 9/33 (27%) | 2.7 (1.3 to 5.6) | 0.2 (0.1 to 0.3) | 4/9 (44%) | 0.9 (0.4 to 2.2) | -0.03 (-0.4 to 0.4) | ||
| No | 16/160 (10%) | Baseline | 9/19 (47%) | Baseline | ||||
| Anosmia (Loss of Smell) | ||||||||
| Yes | 2/5 (40%) | 3.3 (1.0 to 10.2) | 0.3 (-0.2 to 0.7) | 0/2 (0%) | _ | -0.5 (-0.7 to -0.3) | ||
| No | 23/188 (12%) | Baseline | 13/26 (50%) | Baseline | ||||
| Ageusia (Loss of Taste) | ||||||||
| Yes | 3/4 (75%) | 6.4 (3.2 to 12.8) | 0.6 (0.2 to 1.1) | 1/3 (33%) | 0.7 (0.1 to 3.6) | -0.1 (-0.7 to 0.4) | ||
| No | 22/189 (12%) | Baseline | 12/25 (48%) | Baseline | ||||
Army/civilian/family status is not included as the results are confounded by the transmission dynamics of the virus through the barracks with civilians most likely to have recent infection and Army personnel with previous infection.